Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis Clinical Trial

Official title:

A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02544451
• Other study ID #: VX15-809-110
• Status: Completed
• Phase: Phase 3
• Start date: August 2015
• Est. completion date: April 2020

Study information

• Verified date: February 2021
• Source: Vertex Pharmaceuticals Incorporated
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study 110 is a Phase 3, multicenter study in subjects aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation and who participated in Study 109 (NCT02514473) or Study 011B (NCT01897233). Study 110 is designed to evaluate the safety and efficacy of long term treatment of lumacaftor in combination with ivacaftor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 246
• Est. completion date: April 2020
• Est. primary completion date: August 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years and older

Eligibility

Inclusion Criteria:

Subjects entering the Treatment Cohort must meet both of the following criteria:

• Completed study visits up to Week 24 of Study 109 or Week 26 of Study 011B and did not permanently discontinue treatment

• Willing to remain on a stable CF medication through the Safety Follow-up Visit.

Subjects entering the Observational Cohort must meet 1 of the following criteria:

• Completed 24 weeks of study drug treatment in Study 109 or completed 24 weeks of study drug treatment and the Week 26 Safety Follow up in Study 011B.

• Received at least 4 weeks of study drug and completed visits up to Week 24 of Study 109 or Week 26 of Study 011B.

Exclusion Criteria (Treatment Cohort Only):

• History of any comorbidity or laboratory abnormality that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject (e.g., cirrhosis with portal hypertension).

• Pregnant and nursing females.

• Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements.

• History of drug intolerance in the prior study that would pose an additional risk to the subject in the opinion of investigator

• History of poor compliance with study drug and/or procedure in the previous study as deemed by the investigator.

• Participation in an investigational drug trial (including studies investigating lumacaftor and/or ivacaftor).

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis

Intervention

Drug:
• LUM/IVA
Lumacaftor (LUM) 200 mg every 12 hours (q12h)/ivacaftor (IVA) 250 mg q12h (for 6 through 11 years of age). LUM 400 mg q12h/IVA 250 mg q12h (for 12 years and older).
• LUM/IVA
LUM 200 mg q12h/IVA 250 mg q12h (for 6 through 11 years of age).

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Vertex Pharmaceuticals Incorporated

Countries where clinical trial is conducted

United States,  Australia,  Belgium,  Canada,  Denmark,  France,  Germany,  Sweden,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Treatment Period 1 (Treatment Cohorts): Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)		Day 1 up to Week 100
Secondary	Absolute Change in Lung Clearance Index (LCI) 2.5	LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.	From Parent Study Baseline at Week 96
Secondary	Absolute Change in Sweat Chloride	Sweat samples were collected using an approved collection device.	From Parent Study Baseline at Week 96
Secondary	Absolute Change in Body Mass Index (BMI)	BMI was defined as weight in kilograms divided by height in square meter (m^2).	From Parent Study Baseline at Week 96
Secondary	Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score	The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.	From Parent Study Baseline at Week 96
Secondary	Observational Cohort: Safety as Assessed by Serious Adverse Events (SAEs)		Day 1 up to Week 100
Secondary	Absolute Change in LCI 5.0	LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.	From Parent Study Baseline at Week 96
Secondary	Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)	FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.	From Parent Study Baseline at Week 96
Secondary	Relative Change in ppFEV1	FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.	From Parent Study Baseline at Week 96
Secondary	Absolute Change in BMI-for-age Z-score	BMI was defined as weight in kilograms divided by height in m^2. z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.	From Parent Study Baseline at Week 96
Secondary	Absolute Change in Weight		From Parent Study Baseline at Week 96
Secondary	Absolute Change in Weight-for-age Z-score	z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.	From Parent Study Baseline at Week 96
Secondary	Absolute Change in Height		From Parent Study Baseline at Week 96
Secondary	Absolute Change in Height-for-age Z-score	z-score is a statistical measure to describe whether a mean was above or below the standard. A z-score of 0 is equal to the mean and is considered normal. Lower numbers indicate values lower than the mean and higher numbers indicate values higher than the mean.	From Parent Study Baseline at Week 96
Secondary	Absolute Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Domain Score	The TSQM measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed in the total domain score, which ranges from 0 to 100, where higher scores indicate greater satisfaction.	From Parent Study Baseline at Week 96
Secondary	Time-to-first Pulmonary Exacerbation	Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.	From Parent Study Baseline through Week 96
Secondary	Percentage of Participants Having At Least 1 Pulmonary Exacerbation Event	Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.	From Parent Study Baseline through Week 96
Secondary	Number of Pulmonary Exacerbation Events Per Patient-year	Pulmonary exacerbation was defined as the treatment with new or changed antibiotic therapy (intravenous, inhaled, or oral) for greater than or equal to 4 sinopulmonary signs/symptoms.	From Parent Study Baseline through Week 96
Secondary	Rate of Change in LCI 2.5	Rate of change analysis evaluates the change in LCI 2.5 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.	Day 15 after first dose of LUM/IVA through Week 96
Secondary	Rate of Change in LCI 5.0	Rate of change analysis evaluates the change in LCI 5.0 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.	Day 15 after first dose of LUM/IVA through Week 96
Secondary	Rate of Change in ppFEV1	Rate of change analysis evaluates the change in ppFEV1 after long term treatment with LUM/IVA. A rate of change equal to zero would indicate that treatment effects were stable.	Day 15 after first dose of LUM/IVA through Week 96
Secondary	Treatment Period 2: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)		Day 1 up to Week 168